StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Manufacturing Optimization Program by Year

Manufacturing Optimization Program — Cumulative Phase 1 costs incurred to date ($M) ($M)

Pfizer Manufacturing Optimization Program: $1,100M in FY2025, down 8.3% from a year earlier.

Latest, FY2025
1,100
Period ended Dec 31, 2025
Change on a year earlier
-8.3%
1,200 in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-26) ↗

Reported in Form 10-Q / 10-K Note 3 — Restructuring Charges & Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedManufacturing Optimization Program — Cumulative Phase 1 costs incurred to date ($M) ($M)Year on yearSource
FY2025Dec 31, 20251,100-8.3%Form 10-K (filed 2026-02-26) ↗
FY2024Dec 31, 20241,200–Form 10-K (filed 2025-02-27) ↗

Cite this data

StockData. (2026). Pfizer Manufacturing Optimization Program ($M), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-cum-mfg

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.